Previous Article | Next Article ![]()
Journal of Clinical Microbiology, December 2006, p. 4491-4497, Vol. 44, No. 12
0095-1137/06/$08.00+0 doi:10.1128/JCM.01375-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Institute of Basic Medical Sciences,1 Department of Medicine,9 Department of Medical Laboratory Science and Biotechnology,5 Institute of Molecular Medicine, Medical College,8 Department of Statistics, Management College, National Cheng Kung University,7 Institute of Computer Science of Information Education, National University of Tainan, Tainan, Taiwan, Republic of China,6 Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan,2 Liver Unit, Hospital General Universitari Vall d'Hebron, Barcelona, Spain,3 Department of Clinical Virology, Göteborg University, Guldhedsgatan 10B, Goteborg, Sweden4
Received 5 July 2006/ Returned for modification 8 September 2006/ Accepted 22 September 2006
|
|
|---|
|
|
|---|
Several methods for genotyping HBV have been reported, including melting curve analysis (MCA) (16, 19), restriction fragment length polymorphism (RFLP) (7, 8), post-PCR hybridization or line probe assay (4), PCR with genotype-specific primers (9), and enzyme-linked immunosorbent assay-based methods (18). One genotyping method was shown to also quantitate HBV viremia (19), but that method was limited to distinguishing between genotypes B and C, which are prevalent in Asia. In this study, an efficient PCR-based method was developed to combine quantification of HBV DNA and genotyping with differentiation of HBV genotypes A to G. The results showed consistency with currently available viral-load quantification and efficient genotyping. The PCR-based method thus provides a useful tool for rapid and cost-effective diagnosis in areas with different geographical distributions of HBV genotypes.
|
|
|---|
Principle of real-time PCR genotyping by melting curve analysis. The genotyping method was based on MCA with LightCycler hybridization probes as shown in Fig. 1A. The primers and hybridization probes were designed by analyzing 369 full-length HBV nucleotide sequences from the GenBank database, which by alignments and phylogenetic analysis using the Clustal X1.81, GeneDoc2.6.002, and Mega2 programs had been classified into eight genotypes, from A to H. These alignments included, after excluding the sequences of inconclusive genotypes, 69 full-length HBV sequences of type A, 93 of type B, 101 of type C, 54 of type D, 6 of type E, 27 of type F, 10 of type G, and 9 of type H isolates (1). Thus, a few conserved signature single-nucleotide polymorphisms that could differentiate all genotypes were identified. These polymorphisms were targeted by the LightCycler sensor probes to allow genotype identification by melting temperature (Tm) analysis.
![]() View larger version (14K): [in a new window] |
FIG. 1. Primers and hybridization probes on melting curve analysis. (A) The workflow used for differentiating the seven HBV genotypes A to G with two-step melting curve analysis. With the set 1 amplicon, real-time PCR was used for quantification, with simultaneous melting curve analysis for differentiating genotypes into two groups. According to the distinct melting temperature, single genotypes can be further differentiated with either set 2-1 or set 2-2 reaction mixtures. (B) The relevant portions of the HBV genome with binding sites for the different primers and probes. , forward primer; , reverse primer; , sense probe; , anchor probe.
|
Real-time PCR amplification of HBV using LightCycler. The serum HBV DNA was extracted with a Viogene extraction kit, and real-time PCR was then performed on a LightCycler instrument (Roche Diagnostics Applied Science) using primers and probes described in Table 1 and Fig. 1B. The PCR was run in a total volume of 10 µl containing 2.5 µl of DNA template, 1 µl of LightCycler FastStart DNA Master Hybridization Mixture (Taq DNA polymerase, PCR buffer, 10 mM MgCl2, and a deoxynucleoside triphosphate mixture) (Roche Diagnostics Applied Science), 1.2 µl of 25 mM MgCl2, 0.075 µl of 20 µM (each) of the probes, and 0.5 µl of 5 µM of each primer. The amplification using set 1 (ACDG/BEF set) and set 2-1 (B/E/F set) amplicons was performed as follows: initial hot-start denaturation at 95°C for 10 min, followed by 45 cycles of denaturation at 95°C for 10 s, annealing at 53°C for 10 s, and extension at 72°C for 15 s. The programmed temperature transition rate was 20°C/s for denaturation/annealing and 3°C/s for extension. Real-time PCR monitoring was achieved by measuring the fluorescence at the end of the annealing phase for each cycle. After PCR, a melting curve was generated by holding the reaction mixture at 95°C for 10 s and then lowering the temperature to 48°C at a transition rate of 20°C/s and holding it for 60 s. This was followed by heating the reaction mixture slowly at a transition rate of 0.1°C/s to 80°C with continuous collection of fluorescence at 640 nm. The melting curve and quantitative analyses were conducted by using LightCycler analysis software version 3.5 following the manufacturer's instructions (Roche Diagnostics Applied Science). For the set 2-2 amplicon (the A/CD/G set plus the C/D set), the PCR was the same as that for set 1 and set 2-1, except for extension at 72°C for 20 s.
|
View this table: [in a new window] |
TABLE 1. PCR primers and probes in the amplicons used for HBV quantification and genotyping
|
Alternative genotyping of HBV genotypes A, C, D, and G by type-specific multiplex PCR. Because the accuracy of the second-step melting curve analysis was probably influenced by complicated conditions during differentiation of the group of four genotypes (A, C, D, and G), an alternative genotyping method using type-specific multiplex PCR was designed. This PCR utilized one universal forward primer (5' nucleotides [nt] 2305 to 2325) and a mixture of four HBV genotype-specific reverse primers: 5'-TAGGGGACCTGCCTCGGTC-3' (nt 2413 to 2395) for genotype A, 5'-TTCATTAACTGTAAGAGGGCCYAAAT-3' (nt 2659 to 2634) for genotype C, 5'-GATTGCTGGTGGAAAGATTCTGC-3' (nt 2952 to 2907) for genotype D, and 5'-ACTAACATTGGGAAGCTGGAGATGC-3' (nt 2497 to 2473) for genotype G. Multiplex PCR was carried out in a total volume of 50 µl, which contained 0.5 µl of each primer (20 mM), 2 ml deoxynucleoside triphosphate (5 mM), 5 µl 10x Tag reaction buffer, and 10 µl template and water for a total volume of 50 µl. The thermocycler (GeneAmp PCR System 9600; Perkin-Elmer) was programmed to incubate the samples for 5 min at 94°C, followed by 40 cycles consisting of 94°C for 1 min, 59°C for 1 min, and 72°C for 2 min. After the PCR, electrophoresis of the amplified products was completed on a 4% agarose gel, which was stained with ethidium bromide and evaluated under UV light. The multiplex PCR produced different amplicon sizes for genotypes A, C, D, and G, with 109, 349, 609, and 187 bp, respectively.
Direct-sequencing analyses. For samples with discordant results between the PCR-based method and PCR-RFLP, direct sequencing of the HBV complement genome and phylogenetic analysis was conducted (13, 15). HBV amplicons were then subjected to cycle sequencing using ABI PRISM Big-Dye kits (Applied Biosystems, Foster City, CA) and subsequent reading of the sequence using an ABI 3100 Genetics Analyzer. If the genotyping results suggested a mixed infection, the HBV isolates were cloned into a pGEM plasmid and then analyzed by sequencing of five clones.
Statistical methods. The interclass correlation between three duplication experiments in each individual run was calculated to evaluate the reproducibility of the developed genotype quantification method. The Pearson correlation between different runs was also calculated. The correlation between our quantification method and the Roche Amplicor HBV monitor test was evaluated by Pearson correlation. All statistics analyses were conducted using the SPSS statistical package, version 11.0.
|
|
|---|
![]() View larger version (15K): [in a new window] |
FIG. 2. Quantification of the virus by real-time PCR with set 1. (A) Linear regression of the standards ranging from 102 to 1013 copies/ml was determined by using the "second derivative maximum" method. The standard curve showed a regression coefficient, r, of 1.00; a mean squared error of 0.138; an intercept of 47.03; and a slope of 3.293. (B) Comparison of the quantification assay with the Roche Amplicor assay for HBV quantification.
|
![]() View larger version (36K): [in a new window] |
FIG. 3. Representative results for melting curve analysis of clinical samples with genotypes A to G. (A) Differentiation into the group of genotypes (B, E, F) and genotypes (A, C, D, G) with the set 1 amplicon. (B) Differentiating genotypes B, E, and F into single genotypes with the set 2-1 amplicon. (C) Differentiating genotypes A, C, D, and G into single genotypes with the set 2-2 amplicon. In addition, the representative results of each genotype (left), and the results of many clinical samples (right) are shown. The melting temperature for each genotype is indicated with a vertical line.
|
When the results by melting point and PCR-RFLP genotyping were congruent, they were considered accurate. When the results were conflicting, accuracy was assessed by comparison with sequencing. Assessed in this way, the overall accuracy of the melting curve genotyping was 92.3%, compared to 87.0% for RFLP (Table 2). The melting point typing, however, was more accurate with the set 1 amplicon and the set 2-1 amplicon than with the set 2-2 amplicon (99.1% and 97.0% versus 87.9%) because of the higher genotypic specificity of the polymorphisms at nt 225 and nt 706. Tm shift from expected values was relatively common, particularly in genotype C, and sequencing showed that this was due to 1- or 2-nucleotide variations in the segment targeted by the sensor or the anchor probes. Accordingly, identification of genotypes B, E, F, and G was more accurate (98.7%, 100%, 100%, and 100%) than that of genotypes A, C, and D (88.2%, 80.9%, and 85.7%).
|
View this table: [in a new window] |
TABLE 2. Comparison between HBV genotypic analysis using two-step melting curve analysis with different amplicons and PCR-RFLP
|
Detection of HBV mixed infections with melting curve analysis. Although there were no cases of mixed-genotype infection among the samples, the power of the set 1 amplicon in detecting mixed viral infections was evaluated. By mixing two plasmids corresponding to genotypes B and G with various proportions of mixtures ranging from 1:1 to 1:9 and a total concentration of 108copies/ml, the detection sensitivity was 10% for the minor population (Fig. 4).
![]() View larger version (17K): [in a new window] |
FIG. 4. Determination of HBV mixed infection by melting curve analysis. Different proportions of mixtures of genotype B and G plasmids are indicated.
|
|
|
|---|
The accuracy of genotyping was verified by analyzing 441 clinical samples representing genotypes A to G. Overall, the MCA typing provided an accuracy of 92.3%, which was better than that observed for RFLP (87%). For differentiating genotypes B, E, and F by MCA, the accuracy was even higher, up to 96.1%. Due to the appearance of point mutations that altered the melting point, differentiation of genotypes A, C, and D was uncertain in some cases (overall accuracy, 88%). Therefore, an alternative typing method based on multiplex PCR was developed and applied to these samples, allowing correct typing of 99%.
An advantage with this new method is that the genotype is obtained directly from the PCR without further processing. Moreover, the method was found to have higher precision in genotyping and sensitivity for mixed-genotype detection equal to or higher than that of RFLP. A limitation of the method is that the genotype is not identified by a single reaction. We suggest that typing be done in a stepwise manner, the first step separating genotype ACDE from BFG, and the second identifying the genotype within the ACDE or BFG group. The higher cost-effectiveness of this approach is important when the assay is run on LightCycler instruments with only 32 reaction capillaries, particularly if larger sets of samples are genotyped, for example, in clinical studies. If amplification is instead run in the 96-well format with three reaction mixtures (set 1, set 2-1, and set 2-2 amplicons) in parallel, e.g., on a LightCycler 96 instrument, the genotype may alternatively be obtained directly. This would require inclusion of a 72°C extension step (which is otherwise used only in the set 2-2 PCR), but it would allow genotyping of 32 samples per run.
Genotype H was recently identified in Central America. After analyzing genotype H isolates from GenBank, we predict that genotype H will have the same melting point as genotype F, and would thus be typed as F by MCA. However, in most regions of the world, this limitation of the method would be of minor importance.
An additional advantage of the method was the simultaneous quantification, performed with the set 1 amplicon amplification, which targets conserved genomic segments. Previously, a similar method (16) for simultaneous HBV quantification and genotyping was described. However, that method is mainly used for differentiation of genotypes B and C, which are the major HBV genotypes in Asia. The method described in this study allows quantification in parallel with typing of all of the genotypes A to G. The quantification was linear over a broad range of viremia, and its accuracy was documented by comparison with the Roche Amplicor assay. Although the comparison with Amplicor indicated that quantification is accurate for all genotypes, this needs to be confirmed by further analysis of reproducibility panels and clinical samples. An advantage of the Amplicor assay compared to our method is the inclusion of internal inhibition controls and output in IU (by calibration to a WHO standard). On the other hand, our real-time PCR method has a much broader detection range and lower reagent costs. It should be attractive for monitoring patients during antiviral treatment and for research projects when output in the IU format is considered less important.
In summary, this study provides a quick and useful HBV quantification and large-scale genotyping method for genotypes A to G suitable for research and clinical diagnostics in all regions of the world.
Published ahead of print on 4 October 2006. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»